Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9027751 | 1.00 | EPHX1 (0.48) | EPHX1ALDH1A1POLBRECQLMAPT | |
| SCHEMBL9029685 | 1.00 | EPHX1 (0.48) | EPHX1ALDH1A1POLBRECQLMAPT | |
| SCHEMBL4191188 | 0.92 | MAOA (0.47) | EPHX1ALDH1A1MAPTGAASMN1; SMN2 | |
| SCHEMBL5022149 | 0.89 | ALDH1A1 (0.41) | EPHX1ALDH1A1POLBRECQLMAPT | |
| SCHEMBL1908699 | 0.85 | MAOA (0.43) | EPHX1ALDH1A1MAPTGAASMN1; SMN2 | |
| SCHEMBL21213732 | 0.83 | SMYD3 (0.49) | GAAMAOA | |
| SCHEMBL12819982 | 0.83 | MAOA (0.42) | EPHX1MAPTGAASMN1; SMN2MAOA | |
| SCHEMBL21198215 | 0.83 | SMYD3 (0.49) | GAAMAOA | |
| SCHEMBL16374937 | 0.83 | SMYD3 (0.49) | GAAMAOA | |
| SCHEMBL24658467 | 0.82 | MAOA (0.38) | ALDH1A1POLBRECQLMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| EP-0535250-B1 | NOVEL COMPOUNDS AND USE THEREOF AS MEDICINE | TSUMURA & CO (JP) | 1996-06-19 | — | — | EP | disclosed |
| EP-0705817-A1 | New cannamide derivatives and their use as allergy inhibitors | TSUMURA & CO. (JP) | 1996-04-10 | — | — | EP | disclosed |
| US-5344845-A | Methyl 4(4-acetoxy-3-methoxycinnamanide and salts as an immunosuppressive drug for allergic reactions | TSUMURA & CO. (JP) | 1994-09-06 | — | — | US | disclosed |
| EP-0535250-A1 | NOVEL COMPOUNDS AND USE THEREOF AS MEDICINE | TSUMURA & CO. (JP) | 1993-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209511-A1 | Benzofuran Derivatives | F12, F2, F3 | EPHX1 3031/4885ALDH1A1 693/4885POLB 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.